Nature Communications (Apr 2018)
Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma
- S. Manier,
- J. Park,
- M. Capelletti,
- M. Bustoros,
- S. S. Freeman,
- G. Ha,
- J. Rhoades,
- C. J. Liu,
- D. Huynh,
- S. C. Reed,
- G. Gydush,
- K. Z. Salem,
- D. Rotem,
- C. Freymond,
- A. Yosef,
- A. Perilla-Glen,
- L. Garderet,
- E. M. Van Allen,
- S. Kumar,
- J. C. Love,
- G. Getz,
- V. A. Adalsteinsson,
- I. M. Ghobrial
Affiliations
- S. Manier
- Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- J. Park
- Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- M. Capelletti
- Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- M. Bustoros
- Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- S. S. Freeman
- Cancer Program, Broad Institute of MIT and Harvard
- G. Ha
- Cancer Program, Broad Institute of MIT and Harvard
- J. Rhoades
- Cancer Program, Broad Institute of MIT and Harvard
- C. J. Liu
- Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- D. Huynh
- Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- S. C. Reed
- Cancer Program, Broad Institute of MIT and Harvard
- G. Gydush
- Cancer Program, Broad Institute of MIT and Harvard
- K. Z. Salem
- Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- D. Rotem
- Cancer Program, Broad Institute of MIT and Harvard
- C. Freymond
- Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- A. Yosef
- Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- A. Perilla-Glen
- Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- L. Garderet
- Department of Hematology, St-Antoine University Hospital
- E. M. Van Allen
- Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- S. Kumar
- Department of Hematology, Mayo Clinic
- J. C. Love
- Cancer Program, Broad Institute of MIT and Harvard
- G. Getz
- Cancer Program, Broad Institute of MIT and Harvard
- V. A. Adalsteinsson
- Cancer Program, Broad Institute of MIT and Harvard
- I. M. Ghobrial
- Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- DOI
- https://doi.org/10.1038/s41467-018-04001-5
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 11
Abstract
Circulating tumor cells (CTCs) and cell-free DNA (cfDNA) enables characterization of a patient’s cancer. Here, the authors analyse CTCs, cfDNA, and tumor biopsies from multiple myeloma patients to show these approaches are complementary for mutation detection, together enabling a greater fraction of patient tumors to be profiled.
